These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18251666)

  • 1. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
    Peppard WJ; Johnston CJ; Urmanski AM
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):83-99. PubMed ID: 18251666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
    Appelbaum PC; Jacobs MR
    Curr Opin Microbiol; 2005 Oct; 8(5):510-7. PubMed ID: 16098786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future treatment options for Gram-positive infections--looking ahead.
    Barton E; MacGowan A
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():17-25. PubMed ID: 19917023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence and management of drug-resistant enterococcal infections.
    Arias CA; Murray BE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):637-55. PubMed ID: 18847403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
    Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
    J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antibiotic agents for bloodstream infections.
    Vergidis PI; Falagas ME
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid for the treatment of drug-resistant infections.
    Herrmann DJ; Peppard WJ; Ledeboer NA; Theesfeld ML; Weigelt JA; Buechel BJ
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):825-48. PubMed ID: 19053895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria.
    Stevens DL
    J Infect; 2009 Sep; 59 Suppl 1():S32-9. PubMed ID: 19766887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recommendations for the treatment of nosocomial infections caused by Gram-positive microorganisms].
    Azanza JR; Barberán J; García-Rodríguez JA; Llinares P; Mensa J; Picazo J; Prieto J; Torre Cisneros J
    Rev Esp Quimioter; 2004 Sep; 17(3):271-88. PubMed ID: 15619658
    [No Abstract]   [Full Text] [Related]  

  • 18. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.
    Sincak CA; Schmidt JM
    Ann Pharmacother; 2009 Jun; 43(6):1107-14. PubMed ID: 19435963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic therapeutic options for infections caused by drug-resistant Gram-positive cocci.
    Banwan K; Senok AC; Rotimi VO
    J Infect Public Health; 2009; 2(2):62-73. PubMed ID: 20701863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.